Bellicum receives $5.7M in funding for CaspaCIDe

Houston, TX-based biotech Bellicum Pharmaceuticals gained a $5.7 million influx of cash to continue testing and manufacturing its cancer therapy, CaspaCIDe. The therapy is being tested for Graft versus Host Disease, a side effect that can occur from bone marrow transplants and is often fatal. Early results from trials show promising results that have reduced hematologic malignancies. The funding came from the Cancer Prevention and Research Institute of Texas. Bellicum release

Suggested Articles

Xcovery's ALK inhibitor shrank tumors in 75% of lung cancer patients, compared to 67% for Pfizer's Xalkori, the first FDA-approved drug of that class.

The FDA accepted the regulatory filing for Biogen's once-failed Alzheimer's drug, aducanumab, with plans to decide its fate by March 7, 2021.

Alexion named a chief diversity officer, while COVID-19 vaccine player has two new members of its C-suite.